-
Improving AD patients' cognitive indicators Innovative oral therapy reaches phase 2b/3 clinical major...
Time of Update: 2021-01-06
AB Science announced today that it has reached its intended primary endpoint in a Phase 2b/3 clinical trial of the oral therapy masitinib in the treatment of patients with mild and moderate Alzheimer's disease.
-
New target path for Alzheimer's disease - Drp1-HK1-NLRP3
Time of Update: 2021-01-06
Source: Science Advances Further mechanism studies have shown that excessive activation of Drp1 in mature OL induces glycolysis defects in the AD model by inhibiting hesitose kinase 1 (HK1; a mitochondrial enzyme that initiates glycolysis), thereby triggering NLRP3-related inflammation.
-
Biopharmaceutical Deal Analysis 2020: Acquisitions breakthrough under the epidemic
Time of Update: 2021-01-06
most of the signed partnerships on respiratory diseases are in the research and development platform/discovery phase (Figure 1), as these pharmaceutical companies want to develop vaccine candidates and antibody therapies based on the latest knowledge about the virus.
-
Ukip anti-epileptic drugs have been approved for new adaptations in China
Time of Update: 2021-01-06
. In August 2018, China's State Drug Administration again approved the listing of the left ethyl iracetam tablet for the treatment of partial seizures (accompanied or not accompanied by secondary comprehensive seizures) in patients with epilepsy in adults and children over 4 years of age.
-
Domestic pharmaceutical companies announced: Hengrui, Howson, Yangzijiang...
Time of Update: 2021-01-06
in general, this year's Chinese pharmaceutical companies have made great progress compared with the past, the rapid rise in the global ranking, can be a side of the rapid development of China's pharmaceutical industry.
-
Forbes "30 under 30" science field...
Time of Update: 2021-01-06
Zibo Chen, a 29-year-old postdoctoral researcher at the California Institute of Technology, is developing a molecular computer that uses artificially designed proteins to transform cells.
Chanyeol Choi, a 29-year-old doctoral student at the Massachusetts Institute of Technology, is developing a large computing device to simulate the human brain.
-
First sound pharmaceutical stroke new drugs must first enter the ® health insurance directory
Time of Update: 2021-01-05
it is worth noting that the prices of most varieties that have been successful in this year's health care negotiations have greatly reduced the medical burden on patients, while also taking into account the value of innovative research and development by enterprises, and further releasing the incentive direction of national policies for innovative drugs.
-
Somaglutide cures Alzheimer's disease! Noor and Nord directly launch 3700 people II...
Time of Update: 2021-01-05
In addition, Novartis conducted an after-the-fact analysis of trial data from three large cardiovascular outcome studies, LEADER, SUSTAIN 6 and PINEER 6, in which 15,820 patients with type 2 diabetes had a moderate follow-up time of 3.6 years and found that 47 people had dementia (early mild Alzheimer's disease), 32 of whom used placebo and 15 with GLP-1 drugs (lilaruptide or Smaglu.
-
Research and development . . 2020 Lung Cancer Major Research Exchange...
Time of Update: 2021-01-05
The study was a randomized double-blind, global, placebo-controlled Phase III clinical study designed to assess the efficacy and safety of Aoxini (n-339) and placebo-assisted therapy (3 years) after surgical complete removal in patients with EGFR-sensitive mutations in the IB-IIIA phase± main endpoint was the researchers' assessment of disease-free survival (DFS) in patients with stage II-IIIA.
-
In-depth inventory: What trends do the FDA's approval of 53 innovative drugs this year represent...
Time of Update: 2021-01-05
Photo Source: Pharmaceutical Mingkangde Content Team Charting: As of December 25, 2020, the proportion of orphan drugs approved by the FDA has gradually increased in the number of approved innovative therapies, reaching a 10-year high.
-
Gilead Tecartus treatment package lymphoma is eligible for European approval
Time of Update: 2021-01-05
the availability of this cell therapy provides an important treatment option for patients in Europe who have been treated with recurring or refractic sleeve lymphoma after at least two BTK inhibitors.
-
The therapeutic potential of interstate-filled stem cells in a variety of pediatric diseases
Time of Update: 2021-01-05
Clinic reports that a 9-year-old leukemia boy who developed a treatment-resistant IV-grade transplant anti-host disease after a bone marrow transplant received in vitro amplified interstummal stem cells from his mother, and that after injection therapy, his symptoms were relieved and showed no signs of heterogenous reactions, the most successful case of survival in such a serious disease.
-
Enhua Pharmaceuticals' "Mida Zolun Injection" was the first to pass a consistent evaluation
Time of Update: 2021-01-05
2. Sedation/anti-anxiety/memory loss prior to or during intravenous injections for diagnosis, treatment, endoscopy (e.g. bronchial, gastroscopic, cystoscopy, coronary analtomy, cardiac catheterization, tumor surgery, radiation procedures, stitching lacerations and other individual medications or in association with other central nervous system inhibitors).
-
FDA approves 139 NDA/BLA applications for near-historic number of innovative drugs...
Time of Update: 2021-01-05
4, ORLADEYOOrladeyo (Berotralstat) is a new, oral, 1 daily, powerful, selective human plasma peptide release enzyme inhibitor developed by BioCryst to prevent hereditary angioedema (HAE) attacks in children and adults 12 years of age and older.
-
TREG Therapy: Hope for the Holy Grail of Kidney Transplantation?
Time of Update: 2021-01-05
How to improve the long-term survival rate of transplants and transplant recipients is the subject of transplantation research, in which the study of immunosuppressants occupies an important position
-
Many large hospital outpatient clinics across the country ushered in adjustment!
Time of Update: 2021-01-05
can be said that in the outbreak prevention and control of the normal situation, public hospitals are also facing greater operational pressure.
-
Sgk1, a new target for Alzheimer's disease
Time of Update: 2021-01-05
the levels of H3K4me3 and its catalytic enzymes in the pre-cortical layer increased significantly (Source: Science Advances) In the Alzheimer's mouse model, the researchers found that the systemic dosage of set1/MLL HMT inhibitor WDR5-0103 significantly reduced levels of H3K4me3 in mice, significantly improved memory-related behavior, and reversed memory impairment in mice.
-
The first three total Tarlig treatment of spinal cord injury after the central
Time of Update: 2021-01-04
Daiichi Sankyo, a Japanese drug company, recently announced that a Phase 3 study to assess the treatment of central nervous pathological pain (CNP) after Tarlige 's treatment of spinal cord injury (SCI) has reached its main end point.
-
The Lancet's latest article reveals that Remegis is safe and effective in preventing migraines
Time of Update: 2021-01-04
team conducted a multicenter, randomized, double-blind, placebo-controlled trial at 92 research centers in the United States to assess the safety and effectiveness of remegis in migraine prevention treatment.
-
"Pharmaceutical Express" level three hospital evaluation standards revised Novarce new drugs approved in China
Time of Update: 2021-01-04
December 29, 2020 / Medical Information List: Level 3 Hospital Review Standards Revised; Redding Pharmaceuticals and Cullinan Oncology reach exclusive licensing partnership for Greater China; AstraZeneca and Mercado receive 3 approvals in Japan; Shishi Mesquibo Zeposia applys for new adaptations; Novartis announces that new allergic conjunctivitis drugs have been officially approved in China...
